DRUG INTERACTIONS WITH TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor)
Drug-drug interactions tool
The Drug-Drug Interactions (DDI) Tool provides the established or predicted effect of TRIKAFTA on other medicinal products or effect of other medicinal products on TRIKAFTA1-4
- The clinical comments are based on drug interaction studies, clinical relevance, or predicted interactions due to elimination pathways
- Drugs shown within a therapeutic class do not represent all possible drugs within the class. Drugs within a therapeutic class may have different metabolic profiles and, therefore, clinical recommendations apply only to the indicated drugs and not the class. The table does not represent all possible drugs or drug classes that a patient could be receiving. For further information, contact your clinical pharmacist
Choose or begin typing the brand or generic drug name or drug class to learn more about potential DDIs
Choose or begin typing the brand or generic drug name or drug class to learn more about potential DDIs
Drug names in the table that are bold are listed in the full Prescribing Information for SYMDEKO.
Drug names in the table that are bold are listed in the full Prescribing Information for TRIKAFTA.
Drug interaction profiles1
Clinical considerations for TRIKAFTA are based on drug interaction studies, modeling, other clinical factors, and/or predicted interactions due to elimination pathways. Dose adjustments are required for concomitant use with strong and moderate CYP3A inhibitors.
|
|
Tablets are not actual size.
|
Tablets are not actual size.
|